IFNG and psoriasis: However, clinical trials targeting IFN-γ alone have shown limited efficacy (114), underscoring the multifactorial nature of psoriasis, where single-molecule inhibition often fails to achieve comprehensive symptom control due to redundant inflammatory pathways.